Other Events ·
Nasdaq notifies Akebia Therapeutics of non-compliance with the $1.00 minimum bid price
AKBAAkebia Therapeutics, Inc.
On October 21, 2026, Nasdaq notified Akebia Therapeutics that its common stock closed below $1.00 per share for 30 consecutive business days, violating the minimum bid price requirement. The company has an initial compliance period until April 19, 2027, to restore the closing bid price to at least $1.00 for ten consecutive business days. Failure to comply may result in a second compliance period or delisting proceedings. Akebia Therapeutics operates in the biopharmaceutical industry.